Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.77 |
| ▸ | EP300 | Q09472 | 2/20 | 0.77 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.77 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | GFER | P55789 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.71 |
| ▸ | MITF | O75030 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | CASP1 | P29466 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10409886 | 0.92 | RECQL (0.68) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL808104 | 0.87 | EP300 (1.00) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL17298738 | 0.84 | PSD (1.00) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL21511039 | 0.84 | GAA (1.00) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL16863960 | 0.83 | MEN1 (0.75) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL14478903 | 0.82 | EP300 (0.71) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL3260612 | 0.82 | HKDC1 (0.66) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL9769697 | 0.80 | EP300 (0.71) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL11636405 | 0.79 | DDX3X (0.73) | HKDC1EP300KAT2BKAT8GAA | |
| SCHEMBL15894583 | 0.79 | EP300 (1.00) | HKDC1EP300KAT2BKAT8GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12163968-B2 | Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers | BIO-RAD LABORATORIES, INC. (US) | 2024-12-10 | — | — | US | claimed |
| US-12163968-B2 | Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers | BIO-RAD LABORATORIES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4208021-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | Bio-Rad Laboratories, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116097093-A | Preparation of Nucleated RBC (NRBC) analogs for use as reference blood controls in automated blood analyzers | 生物辐射实验室股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022094079-A1 | METHODS OF TREATING CYSTIC FIBROSIS | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022051443-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | BIO-RAD LABORATORIES, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220065878-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | BIO-RAD LABORATORIES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-6265146-B1 | SUPPORT HAVING THEREON AN ORGANIC SILVER SALT, A BINDER, A PHOTOSENSITIVE SILVER HALIDE, AN INFRARED-SENSITIZING DYE AND A HETEROATOM CONTAINING MACROCYCLIC COMPOUND. | KONICA CORPORATION (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1058151-A1 | Silver halide photothermographic material | KONICA CORPORATION (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-1037102-A1 | Image forming method of photothermographic material | KONICA CORPORATION (JP) | 2000-09-20 | — | — | EP | disclosed |
| EP-1033618-A1 | Thermally developable photosensitive material | KONICA CORPORATION (JP) | 2000-09-06 | — | — | EP | disclosed |
| US-4546075-A | TETRAZOLE, BENZOTHIAZOLE, BENZOXAZOLE, OR BENZIMIDAZOLE COMPOUNDS | FUJI PHOTO FILM CO., LTD. (JP) | 1985-10-08 | — | — | US | disclosed |
| US-4504568-A | Sensitive silver halide photothermographic materials for producing dye images | EASTMAN KODAK COMPANY (US) | 1985-03-12 | — | — | US | disclosed |
| US-4452885-A | USING THRIHALOMETHYL-3,4-OXADIAZOLES AS ANTIFOGGING AGENTS | FUJI PHOTO FILM CO., LTD. (JP) | 1984-06-05 | — | — | US | disclosed |
| US-4281060-A | STABLE PHOTOGRAPHIC FILMS HAVING A COATING CONTAINING A POLYISOCYANATE OR A POLYISOCYANATE CONTAINING CARBAMATE GROUPS; WEAR RESISTANCE | FUJI PHOTO FILM CO., LTD. (JP) | 1981-07-28 | — | — | US | disclosed |
| US-4104064-A | Photoelectrophoretic imaging method employing dinaphtho-furan-dione pigments | XEROX CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
| US-3957829-A | Certain dinaphtho[1,2-b;2',3'-d]-furan-7,12-diones | XEROX CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | CFTR, DAB2IP, CTTN | HKDC1 2753/4885EP300 2401/4885KAT2B 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.